Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

ValiRx chief says company is at an exciting phase as it updates on two key cancer candidates

Chief executive, Dr Satu Vainikka, said she looked forward to the “successful crystallisation of substantial value for patients and shareholders"
researcher filling a sample tray
The company has made significant clinical progress with both its drug candidates

ValiRx Plc (LON:VAL) said “commercial activity” around its lead cancer drug candidate has continued as it updated on both VAL401 and next in the queue, VAL201.

Chief executive, Dr Satu Vainikka, said she looked forward to the “successful crystallisation of substantial value for patients and shareholders".

“Since the pharmaceutical industry is increasingly looking for novel new therapies in the oncology arena, I believe we are in a new and very exciting phase,” she explained.

“VAL401 has demonstrated therapeutic efficacy, VAL201 is increasingly showing its therapeutic potential and our pre-clinical compounds and platform continue to progress along the value-chain and towards the clinic.”

Lung cancer treatment 

Preparations are currently being made to take the former which is being developed to tackle lung cancer, into final-stage clinical trials.

ValiRx said the principal investigators have now approved and signed the clinical study report and that the process of submission to and approval by the local ethics committees has commenced. 

“Detailed discussions are in progress in respect to a pivotal phase III trial,” the company said in its update. 

“Partners external to ValiRx and ValiSeek will have substantial input into the trial design, with first dosing anticipated next year.”

VAL201, meanwhile, has demonstrated “consistently high” safety and tolerability in hormone-sensitive and hormone-resistant prostate cancer patients taking part in the firm’s phase I/II trial.

Early inspection of data

Researchers have also made an inspection of the data derived from the original dosing regimen.

Highlighted was a dose-related impact on patients' physiology and chemistry.

Affected was androgen PSA (which regulates the expression of prostate cancer cells) as well as various cell and protein turnover factors important in the treatment of cancer. 

“These are in line with anticipated outcomes as far as cancer reduction is concerned,” the company added.

View full VAL profile View Profile

ValiRx Plc Timeline

Related Articles

Graphic of person pointing to different parts of the body
May 14 2018
Paradigm’s share price has increased more than 60% in the last month and it was up more than 12% on Friday.
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year
blood
April 01 2018
The company is in the process of raising £5mln, with a possible further £1mln through a share issue at 52.5p

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use